1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Metrics vs Peers
3. Price Chart
4. Valuation
5. Offer Terms
6. Financial Statements
Discussion
Research report, target price, DCF and forensic scores are for subscribers. View plans
Symbol
XLO
Listed on
2021-10-22
Sector
Health Care
Subsector
Pharmaceuticals
Offer Price
$16.00
first filed $16.00–$18.00Shares Offered
7.35M
27.47M
$426.7M
26.8%
Implied Upside vs Midpoint
Description
We are a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. We have built our geographically precise solutions, or GPS, platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index by geographically localizing their activity inside tumors. Current immuno-oncology, or I-O, therapies have curative potential for patients with cancer; however, their potential is significantly curtailed by systemic toxicity that results from activity of the therapeutic molecule outside the tumor microenvironment, or TME. Our molecules are engineered to localize activity within the TME with minimal systemic effects, resulting in the potential to achieve enhanced anti-tumor activity. We are advancing a number of geographically precise, or tumor-selective, agents through various stages of development. Our most advanced product candidates are XTX101, an anti-cytotoxic T-lymphocyte-associated protein 4, or anti-CTLA-4, monoclonal antibody, or mAb, and XTX202, an interleukin 2, or IL-2, therapy. In June 2021, the U.S. Food and Drug Administration, or FDA, cleared our investigational new drug application, or IND, for XTX101, and we recently initiated our Phase 1/2 trial to evaluate XTX101 in patients with solid tumors. In addition, in October 2021, the FDA cleared our IND for XTX202. We anticipate initiating a Phase 1/2 trial to evaluate XTX202 in multiple solid tumor types in the first quarter of 2022. We are also advancing our tumor-selective IL-12 product candidate, XTX301, with the goal of submitting an IND in the second half of 2022, and we are currently pursuing preclinical studies for our tumor-selective IL-15 product candidate, XTX401. We also plan to continue to leverage our GPS platform to develop additional immunotherapies, including product candidates with a range of tumor targeting approaches. --- Our principal executive offices are located at 828 Winter Street, Suite 300, Waltham, Massachusetts 02451, and our telephone number is (617) 430-4680. Our website address is www.xiliotx.com.
| Metric | Value | Peer median | Among peers | |
|---|---|---|---|---|
Net cash / market cap | 4.5% | 5.1% | ||
Debt / equity | 0.00 | 0.00 | ||
Current ratio | 0.93 | 17.41 | ||
9 premium metrics: DCF value / price, Growth the price needs: how common, Last 12 months vs full year and 6 more Unlock | ||||
▼ Priced at $16.00, 6% below the midpoint of the first filed range ($16.00–$18.00, 2021-10-18).
Each filing is plotted ahead of the first trading day on the price chart.
| Filed | Form | Price range | Price | Shares offered | Deal size |
|---|---|---|---|---|---|
| 2021-10-18 | S-1/A | $16.00–$18.00 | — | 7,353,000 | $125.0M |
| 2021-10-20 | S-1/A | — | $11.69 | 39,723,312 | $464.4M |
| 2021-10-22 | 424B4 | — | $16.00 | 7,353,000 | $117.6M |
Xilio Therapeutics, Inc. income statement and balance sheet, FY Dec 2021 to FY Dec 2025, as reported in SEC filings.
| Metric | FY Dec 2021after listing | FY Dec 2022after listing | FY Dec 2024after listing | FY Dec 2025after listing |
|---|---|---|---|---|
| Revenue | — | — | $6.3M | $43.8M |
| Operating income | ($75.0M) | ($89.1M) | ($60.6M) | ($42.0M) |
| Net income | ($75.8M) | ($88.2M) | ($58.2M) | ($35.0M) |
| Revenue growth | — | — | — | 590% |
| Operating margin | — | — | −955% | −95.9% |
| Net margin | — | — | −918% | −80.1% |
| Metric | FY Dec 2021after listing | FY Dec 2022after listing | FY Dec 2024after listing | FY Dec 2025after listing |
|---|---|---|---|---|
| Total assets | $218M | $139M | $71.1M | — |
| Total liabilities | $32.6M | $33.5M | $53.5M | — |
| Total equity | $185M | $106M | $17.6M | — |
| Cash & equivalents | $198M | $120M | $55.3M | — |